An epigenome-wide association study of metabolic syndrome and its components

Marja-Liisa Nuotio*, Natalia Pervjakova, Anni Joensuu, Ville Karhunen, Tero Hiekkalinna, Lili Milani, Johannes Kettunen, Marjo-Riitta Järvelin, Pekka Jousilahti, Andres Metspalu, Veikko Salomaa, Kati Kristiansson & Markus Perola

The role of metabolic syndrome (MetS) as a preceding metabolic state for type 2 diabetes and cardiovascular disease is widely recognised. To accumulate knowledge of the pathological mechanisms behind the condition at the methylation level, we conducted an epigenome-wide association study (EWAS) of MetS and its components, testing 1187 individuals of European ancestry for approximately 470,000 methylation sites throughout the genome. Methylation site cg19693031 in gene TXNIP — previously associated with type 2 diabetes, glucose and lipid metabolism, associated with fasting glucose level ($P = 1.80 \times 10^{-8}$). Cg06500161 in gene ABCG1 associated both with serum triglycerides ($P = 5.36 \times 10^{-9}$) and waist circumference ($P = 5.21 \times 10^{-9}$). The previously identified type 2 diabetes–associated locus cg08309687 in chromosome 21 associated with waist circumference for the first time ($P = 2.24 \times 10^{-7}$). Furthermore, a novel HDL association with cg17901584 in chromosome 1 was identified ($P = 7.81 \times 10^{-8}$). Our study supports previous genetic studies of MetS, finding that lipid metabolism plays a key role in pathology of the syndrome. We provide evidence regarding a close interplay with glucose metabolism. Finally, we suggest that in attempts to identify methylation loci linking separate MetS components, cg19693031 appears to represent a strong candidate.

Metabolic syndrome (MetS) is a biologically complex condition encompassing a cluster of risk factors such as central obesity, elevated triglycerides, reduced HDL cholesterol, elevated fasting plasma glucose, and elevated blood pressure. When co-occurring, these risk factors create a 1.7- to 1.9-fold risk for cardiovascular disease and a 3.0- to 6.1-fold risk for type 2 diabetes mellitus compared to individuals without the syndrome. The globally increasing prevalence of type 2 diabetes and cardiovascular disease associated with the underlying obesity pandemic emphasises the importance of efforts aimed at unravelling the complicated biological mechanisms of MetS.

The underlying pathogenesis for MetS as a condition is not completely understood. To date, genetic study methods including candidate gene studies, linkage studies, and genome-wide association studies (GWAS) have enjoyed modest success in finding genetic associations with MetS when treated as a dichotomous trait. By contrast, the majority of the associations identified relate to one of the individual components of MetS with variable pleiotropy accompanying other components. These findings have made it reasonable to hypothesize that MetS may not be a single entity at the genomic level and further raised a question if a specific genomic area that would...
be jointly associated to all of these component phenotypes could be found. In previous GWAS studies the role of lipid metabolism as a major contributor to the MetS phenotypic outcome has been emphasised. Epigenetics might serve as one of the factors linking the individual components of the MetS phenotypic outcome. Thus far, only a few studies have successfully identified epigenetic regions and individual markers associated with separate MetS components and only four epigenetic markers have been reported to be associated with MetS as a whole.

We therefore conducted an epigenome-wide association study (EWAS) of MetS and its components using whole blood methylation levels in order to test the association (i) between methylation (CpG) and MetS as a binomial trait, as well as (ii) between methylation (CpG) and individual MetS components to shed light on the metabolic interplay underlying this complex phenotype.

**Materials and methods**

**Study population.** Our study included two populations of Finnish ancestry: a discovery cohort consisting of 517 individuals (the National FINRISK Study, DILGOM), as well as a replication cohort consisting of 670 individuals (the Northern Finland Birth Cohort 1966). Local research ethics committees approved both studies (Coordinating Ethics Committee of the HUS Hospital District for DILGOM, decision numbers 229/E0/2006 and 332/13/03/00/2013, respectively and The Ethical Committee of the Northern Ostrobothnia Hospital District for NFBC1966, decision number 1/2012). All experiments were performed in accordance with relevant guidelines and regulations.

**The national FINRISK study.** FINRISK surveys consist of cross-sectional, population-based studies conducted every five years between 1972 and 2012 to monitor the risk of chronic diseases in Finland. Each survey included a questionnaire and a clinical examination during which a blood sample was drawn. Data are linked to the national electronic healthcare registers for cardiovascular disease and other health outcomes. Our study consisted of eligible individuals from a specific subset examined for metabolic traits during the 2007 FINRISK survey. The DILGOM study (The Dietary, Lifestyle, and Genetic Determinants of Obesity and Metabolic Syndrome) was collected as an extension of the FINRISK 2007 survey. This subset consisted of a total sample size of 5025 individuals aged between 25 and 74, of whom we studied 517 individuals from the Helsinki and Vantaa region using various omics.

![Table 1](image)

Table 1. Sample characteristics. Data is given as mean (SD) or %. DILGOM dietary, lifestyle, and genetic determinants of obesity and metabolic syndrome, NFBC1966 Northern Finland Birth Cohort 1966, MetS metabolic syndrome, HDL high-density lipoprotein. *The number of study participants in DILGOM refers to the individuals for whom methylation data were available. Sample sizes vary between analysed traits as described in Supplementary material.
analyses were performed using the Bioconductor package minfi. Methylation with 94% power and differences up to 2% at 28% power were able to be detected.

Analyses within the discovery sample of approximately 500 individuals, differences up to 20% in CpG-specific intensity values was applied. A detection \( P \) value for each CpG probe were calculated according to Illumina’s recommendations using \( \beta = M/(M + U + 100) \). The difference in the distribution of \( \beta \) values for type I and type II probes was corrected using subset-quantile within array normalisation (SWAN)\(^{17}\). Detection \( P \) values were obtained for every CpG probe in every sample. Failed positions were defined as signal levels lower than background from both methylated and unmethylated channels. Probes with a detectable methylation level in <5% of samples (\( P < 0.01 \)) were excluded. In addition, the CpG sites on the X and Y chromosomes were discarded, which resulted in 468,809 CpG probes for further analysis.

In the DILGOM cohort, the methylation data processing and quality control analyses were performed using the Bioconductor package minfi\(^{18}\). Pre-normalised raw data were used to convert the intensities from the red and the green channels into methylated (M) and unmethylated (U) signals. Beta values for each CpG probe were calculated according to Illumina’s recommendations using \( \beta = M/(M + U + 100) \). The difference in the distribution of \( \beta \) values for type I and type II probes was corrected using subset-quantile within array normalisation (SWAN)\(^{17}\). Detection \( P \) values were obtained for every CpG probe in every sample. Failed positions were defined as signal levels lower than background from both methylated and unmethylated channels. Probes with a detectable methylation level in <5% of samples (\( P < 0.01 \)) were excluded. In addition, the CpG sites on the X and Y chromosomes were discarded, which resulted in 468,809 CpG probes for further analysis.

In the DILGOM cohort, quality control and normalisation for DNA methylation data were performed based on the CPACOR pipeline\(^{18}\) with minor adaptations. The pipeline uses 30 PCs as covariates to control for technical confounding. Data were first retrieved using the minfi R package\(^{16}\), and the Illumina Background Correction to the intensity values was applied. A detection \( P \) value threshold was set to \( P < 1 \times 10^{-10} \), and samples with a call rate <98% were excluded. Quantile normalisation was performed separately for six probe-type categories using R package limma\(^{19}\). These normalised intensity values were used to calculate the \( \beta \) value at each CpG site. A principal component analysis was performed for HM450K control probes, and the first 30 principal components were used as additional explanatory variables in subsequent regression models in both, DILGOM and NFBC1966 cohorts. In both DILGOM and NFBC1966, white blood cell subpopulation estimates were acquired using the software provided by Houseman et al.\(^{20}\), and these subpopulation estimates were also added to regression models as explanatory variables. Further exclusions of individuals from DILGOM and NFBC1966 data were performed before association analyses, based on outlier-status and gender mismatches (Supplementary material).

Power calculation. Power calculation for DILGOM cohort was performed with pweWAS\(^{21}\). For binary analyses within the discovery sample of approximately 500 individuals, differences up to 20% in CpG-specific methylation with at 94% power and differences up to 2% at 28% power were able to be detected.

### Table 2. Definition of metabolic syndrome (MetS) according to the International Diabetes Federation (IDF).

| Condition                                      | Threshold/Indication                                      |
|------------------------------------------------|-----------------------------------------------------------|
| Triglycerides                                  | ≥ 1.7 mmol/l or medication for elevated triglycerides     |
| HDL                                            | < 1.03 mmol/l in men and < 1.3 mmol/l in women or a medication to reduce HDL cholesterol |
| Blood pressure                                 | ≥ 130 mmHg (systolic) or ≥ 85 mmHg (diastolic) or a diagnosis or medication for hypertension |
| Fasting plasma glucose                         | ≥ 5.6 mmol/l or a diagnosis or medication for type 2 diabetes |

**The Northern Finland Birth Cohort 1966 (NFBC1966).** The Northern Finland Birth Cohort 1966 (NFBC1966) is a population-based prospective birth cohort consisting of all mothers in the two northern-most provinces of Finland with children whose expected date of birth fell during 1966\(^{22}\). In total, 12,058 live-born children were recruited into the cohort. In 1997, a health and lifestyle questionnaire was sent to all living cohort members with a known address (\( n = 11,322 \)). Those cohort members living in Northern Finland and in the Helsinki area (\( n = 8,463 \)) were also invited for a clinical examination, of whom 6033 attended. Information on smoking and alcohol use was obtained from the questionnaire. Descriptions of the methodologies used to measure the waist circumference (WC), triglycerides, HDL, systolic and diastolic blood pressure, and plasma glucose levels for the study sample are described in detail in Supplementary material. Informed consent and written permission were obtained from the study participants at both 31 and 46 years of age.

DNA extraction and methylation array analysis. In the DILGOM cohort, whole blood samples were obtained from 517 individuals (\( n = 239 \) men and \( n = 278 \) women). All subjects were older than 18 years, with a mean age of 51.9 years, and provided their written informed consent for the use of their DNA sample for research.

DNA was extracted from 10-ml whole-blood peripheral white blood cells using the NucleoSpin Tissue kit (Macherey-Nagel GmbH, Düren, Germany) with the salting-out method using 10 M ammonium acetate. DNA was precipitated in isopropanol, washed in 70% ethanol, and resuspended in 1X TE buffer. The purity and concentrations of the DNA samples were measured by spectrophotometer (NanoDrop \( \text{ND1000; Thermo Fisher Scientific Inc., Waltham, MA, US} \)). From each sample, 600 ng of genomic DNA was bisulfite modified using the EZ DNA Methylation kit (Zymo Research Orange, California, US) according to the manufacturer’s recommendations for the Illumina Infinium Assay. After purification, 4 µl of each bisulfite-converted DNA sample was used for hybridisation on the Infinium Human Methylation 450 BeadChip (HM450K) following the Illumina Infinium HD Methylation protocol with the original IDAT files extracted from the HiScan scanner.

In NFBC1966, DNA methylation was extracted after a 31-year follow-up period for a random sample of 807 participants for whom complete follow-up data were available (postal questionnaire and clinical examination at 31 as well as 46 years of age). DNA methylation was further measured using the HM450K assay.

Methylation normalisation. In the DILGOM cohort, the methylation data was processed and quality control analyses were performed using the Bioconductor package minfi\(^{18}\). Pre-normalised raw data were used to convert the intensities from the red and the green channels into methylated (M) and unmethylated (U) signals. Beta values for each CpG probe were calculated according to Illumina’s recommendations using \( \beta = M/(M + U + 100) \). The difference in the distribution of \( \beta \) values for type I and type II probes was corrected using subset-quantile within array normalisation (SWAN)\(^{17}\). Detection \( P \) values were obtained for every CpG probe in every sample. Failed positions were defined as signal levels lower than background from both methylated and unmethylated channels. Probes with a detectable methylation level in <5% of samples (\( P < 0.01 \)) were excluded. In addition, the CpG sites on the X and Y chromosomes were discarded, which resulted in 468,809 CpG probes for further analysis.

In NFBC1966, quality control and normalisation for DNA methylation data were performed based on the CPACOR pipeline\(^{18}\) with minor adaptations. The pipeline uses 30 PCs as covariates to control for technical confounding. Data were first retrieved using the minfi R package\(^{16}\), and the Illumina Background Correction to the intensity values was applied. A detection \( P \) value threshold was set to \( P < 1 \times 10^{-10} \), and samples with a call rate <98% were excluded. Quantile normalisation was performed separately for six probe-type categories using R package limma\(^{19}\). These normalised intensity values were used to calculate the \( \beta \) value at each CpG site. A principal component analysis was performed for HM450K control probes, and the first 30 principal components were used as additional explanatory variables in subsequent regression models in both, DILGOM and NFBC1966 cohorts. In both DILGOM and NFBC1966, white blood cell subpopulation estimates were acquired using the software provided by Houseman et al.\(^{20}\), and these subpopulation estimates were also added to regression models as explanatory variables. Further exclusions of individuals from DILGOM and NFBC1966 data were performed before association analyses, based on outlier-status and gender mismatches (Supplementary material).

Power calculation. Power calculation for DILGOM cohort was performed with pweWAS\(^{21}\). For binary analyses within the discovery sample of approximately 500 individuals, differences up to 20% in CpG-specific methylation with at 94% power and differences up to 2% at 28% power were able to be detected.
**Epigenome-wide association study (EWAS).** In the discovery analysis of the DILGOM cohort, the association between the M value for all 468 809 CpG probes (as outcome variable) and MetS, as well as its six individual components, were tested using regression analysis fitting generalised linear models (glm) using the R software program, version 3.3.1\(^{22}\). Analyses were adjusted for age, sex, smoking status (defined either as current or never/ex-smokers), alcohol consumption (grams/week), cell subtype proportion, study- specific technical covariates (described in detail in Supplementary material), and the first five genetic principal components of the data to control for potential population substructure.

**Replication analysis.** Association analysis of a total of 33 CpG probes was replicated in an independent population sample (NFBC1966, \(n=670\), Supplementary Table 1, Supplementary Fig. 1). The 33 CpG probes were selected for replication by generating Q–Q probability plots of the discovery EWAS results of MetS and its individual components and further verifying selected probes not to be false positive discoveries using permutation analysis. The EWAS results of those 33 CpG probes clearly deviated from the expected line of the Q–Q probability plots. In permutation analysis of each probe we first 1) randomly re-assigned the probe signal values between the study participants while keeping their phenotype data untouched, and then 2) tested for an association between the probe and the phenotypes as described above for the original association analysis. We repeated this procedure 1000 times and calculated how many occurrences of a \(P\) value smaller than the \(P\) value from the original association analysis was observed. For all 33 selected probes, the count was less than 1%. The replication analysis for the 33 CpG probes was performed using the same analytical protocol used in the discovery analysis for the DILGOM cohort.

**Meta-analysis.** Summary statistics from both cohorts were meta-analysed using an inverse-variance weighted fixed-effect model, using the GWAMA software program\(^{23}\).

**Conditional analysis.** To investigate the independence of the replicated methylation signals from the possible underlying genetic effect (DNA variation expressed as an SNP effect), a conditional linear regression analysis was performed for selected, successfully replicated probes (\(N=5\)). First, SNPs located ± 5 Mb from the genomic position of each replicated methylation probe were tested for an association with the phenotype in question (Supplementary Fig. 2). The strongest associating SNP (based on their association \(P\) value) was then used as a covariate in the regression analysis where association between the methylation probe and phenotype was tested.

**Gene expression data processing and analysis.** Sample collection and data processing is described in detail in Inouye et al.\(^{24}\). In brief, RNA was hybridized to Illumina HT-12 v3 BeadChip arrays. The background corrected probes were subjected to quantile normalization for each array at the strip-level. Technical replicates were combined by bead count weighted average and replicates with Pearson correlation coefficient < 0.94 or Spearman’s rank correlation coefficient < 0.60 were removed. Expression values for each probe were log2 transformed.

To investigate the relation between the replicated methylation signals and gene expression, a linear regression analysis was performed for successfully replicated methylation probes located to a gene and equivalent gene transcripts (available for three replicated methylation loci). The same covariates were used to adjust the analyses as those used in discovery EWAS analyses. Possible *trans* effects between selected replicated methylation loci and nearest gene transcripts of other replicated methylation probes were also studied with linear regression analysis.

**Results**

**Epigenome-wide association between DNA methylation and MetS and its components.** We found several differentially methylated CpG methylation sites for MetS and its component traits (WC, fasting glucose, HDL, triglycerides, systolic blood pressure, diastolic blood pressure) across the 468 809 CpG probes analysed in the FINRISK sample on 517 Finnish individuals. In total, 33 probes with methylation M value based \(P\) values ranging from \(P=7.33 \times 10^{-6}\) to \(P=5.08 \times 10^{-8}\), passed permutation based test of statistical significance (\(P_{\text{perm}}<0.05\)) and clearly deviated from the expected line of the Q–Q probability plots of the discovery analysis results (Supplementary Fig. 1). From these, 12 probes associated directly with the MetS status, and all 33 associated with one or more component traits. The 33 probes were further selected for a replication analysis (Fig. 1, Supplementary Table 1).

**Replication, meta-analysis and integration with genetics.** Altogether, five CpG markers were successfully replicated in an independent Finnish sample of 670 individuals at a nominal significance level of \(P<0.05\) (Table 3), and subsequently tested in a meta-analysis combining the discovery and replication cohorts. All replicated associations were for the component phenotypes and none for the MetS case/control status. The methylation site cg19693031 in the TKNI P gene region (chr1:145 441 552) associated inversely with fasting glucose levels in the meta-analysis (\(\beta_{\text{eff}}=-0.076, P=1.80 \times 10^{-8}\)). The methylation site cg06500161 in the ATP-binding cassette, sub-family G (WHIT E), member 1 (ABCG1) gene region (chr21:43 656 587) associated both with serum triglycerides (\(\beta_{\text{eff}}=0.047, P=5.36 \times 10^{-8}\)) and WC (\(\beta_{\text{eff}}=0.003, P=5.21 \times 10^{-9}\)). Two other WC-associated methylation sites were also observed: cg08309687, located within the long intergenic non-protein-coding RNA 649 approximately 8 Mb downstream from the ABCG1 gene region (\(\beta_{\text{eff}}=-0.004, P=2.24 \times 10^{-8}\)), and cg11024682 in the sterol regulatory element binding transcription factor 1 (SREBF1) gene region (chr17:17 730 094) (\(\beta_{\text{eff}}=0.003, P=5.96 \times 10^{-8}\)). Furthermore, methylation site cg17901584 located in the genomic region of HP08874 mRNA (chr1:55 353 706) associated with HDL (\(\beta_{\text{eff}}=0.133, P=7.81 \times 10^{-8}\)).
Similarity among the association results of component phenotypes of MetS. Notable similarity among the association results of the component phenotypes building up the metabolic syndrome as an entity was observed for the 33 CpG probes taken forward for replication (Fig. 1). Several methylation probes associated with both WC and MetS (Fig. 1, Suppl. Table 1). Numerous methylation probes associated with triglycerides and WC, often accompanied by a concurrent association with MetS. Unsurprisingly, several probes were also simultaneously associated both with triglycerides and HDL as well as both with glucose and MetS (Fig. 1).

Two of the five replicated methylation probes simultaneously associated with MetS and with several of its components in the discovery cohort. In addition to the association with triglycerides and WC, methylation site cg06500161 in the ABCG1 gene associated with glucose, HDL, and MetS ($\beta_{\text{eff}} = 0.049$, $P = 7.39 \times 10^{-4}$; $\beta_{\text{eff}} = -0.096$, $P = 2.70 \times 10^{-4}$; $\beta_{\text{eff}} = 0.077$, $P = 7.44 \times 10^{-5}$, respectively). Furthermore, the glucose-associated methylation site cg19693031 in the TXNIP gene region suggestively associated with WC, triglycerides, systolic blood pressure as well as MetS as a condition ($\beta_{\text{eff}} = -0.004$, $P = 2.25 \times 10^{-3}$; $\beta_{\text{eff}} = -0.107$, $P = 1.09 \times 10^{-5}$; $\beta_{\text{eff}} = -0.003$, $P = 3.24 \times 10^{-3}$; $\beta_{\text{eff}} = -0.124$, $P = 6.98 \times 10^{-5}$, respectively), but notably not with HDL (Fig. 1, Suppl. Table 1).
Phenotype | CpG | Position (Chr-bp) GRCh37 | Gene | DILGOM | NFBC1966 | Meta-analysis (DILGOM and NFBC1966)
|-----|-----|----------------|------|--------|--------|-------------------------------|
| Fasting glucose | cg19693031 | 1:145,441,552 | TXNIP | 498 | 0.123 | 0.023 | 8.47E–08 | 670 | 0.050 | 0.017 | 0.003 | 1168 | 0.076 | 0.013 | 1.80E–08 |
| HDL | cg17901584 | 1:55,353,706 | ABCG1 | 498 | 0.156 | 0.034 | 4.63E–06 | 670 | 0.106 | 0.037 | 0.004 | 1168 | 0.133 | 0.025 | 7.81E–08 |
| Triglycerides | cg06500161 | 21:43,656,587 | ABCG1 | 498 | 0.069 | 0.015 | 3.49E–06 | 670 | 0.038 | 0.010 | 1.10E–04 | 1168 | 0.047 | 0.008 | 5.36E–09 |
| WC | cg08309687 | 21:35,320,596 | long intergenic non-protein coding RNA 649 | 497 | 0.004 | 0.001 | 1.75E–06 | 670 | 0.002 | 0.001 | 4.74E–04 | 1167 | 0.003 | 0.0005 | 5.21E–09 |

Table 3. Successfully replicated CpG M value—phenotype associations and the meta-analysis. DILGOM, dietary, lifestyle, and genetic determinants of obesity and metabolic syndrome, NFBC1966 Northern Finland Birth Cohort 1966, HDL high-density lipoprotein, WC waist circumference, CpG cytosine–guanine dinucleotide, Chr chromosome, bp base pair, GRCh37 the Genome Reference Consortium human genome (build 37), SE standard error.

In addition, the remaining replicated methylation probes associated with a few other MetS component phenotypes as follows. The WC--associated site cg08309687, located downstream from the ABCG1 gene region, also associated with triglycerides ($\beta_{\text{eff}} = 0.111$, $P = 5.41 \times 10^{-3}$). CG11024682 in the SREBF1 gene region appeared to associate with triglycerides and MetS ($\beta_{\text{eff}} = 0.034$, $P = 5.21 \times 10^{-3}$; $\beta_{\text{eff}} = 0.067$, $P = 2.11 \times 10^{-5}$, respectively). Despite the general association pattern with the lipid components of MetS, neither cg08309687 nor cg11024682 associated with HDL. Rather, HDL-associated site cg17901584 appeared to also associate with triglycerides and WC ($\beta_{\text{eff}} = -0.056$, $P = 4.44 \times 10^{-3}$; $\beta_{\text{eff}} = -0.003$, $P = 1.28 \times 10^{-3}$, respectively) (Fig. 1, Suppl. Table 1).

Figure 1 shows some general behaviour patterns of MetS component phenotypes (Fig. 1). Notably, the association for the blood pressure components (systolic- and diastolic blood pressure) of MetS behaved rather independently compared to other components. Methylation probe cg19693031 in the TXNIP region emerged as the only methylation probe binding blood pressure to other MetS components. Interestingly, methylation site cg06500161 in the gene ABCG1 appeared to also associate with diastolic blood pressure in addition to the association with triglycerides and WC in the replication cohort (Fig. 2, Supplementary Table 2), despite this association remaining unidentified in the discovery analysis (Fig. 1, Suppl. Table 1).

Examination of the underlying genetic effects. To test the possible underlying genetic effects (DNA variation expressed as an SNP effect) behind the CpG–phenotype associations, we used as a covariate in the conditional analysis the strongest associating SNP ± 5 Mb from the genomic position of each replicated methylation probe for analysis of cg19693031 and glucose, cg17901584 and HDL, cg06500161 and triglycerides, and cg11024682 associated with HDL. Rather, HDL-associated site cg17901584 appeared to also associate with triglycerides and WC ($\beta_{\text{eff}} = -0.056$, $P = 4.44 \times 10^{-3}$; $\beta_{\text{eff}} = -0.003$, $P = 1.28 \times 10^{-3}$, respectively) (Fig. 1, Suppl. Table 1).

Associations of replicated DNA methylation loci and gene expression. We examined the relation of the replicated methylation locus annotated to a gene with gene expression of the gene in question. Gene expression data was available for transcripts of genes TXNIP, SREBF1 and ABCG1 (Table 5). The methylation site cg11024682 annotated to SREBF1 gene body associated inversely with SREBF1 gene transcript ($\beta_{\text{eff}} = -0.136$, $P = 1.69 \times 10^{-6}$) between glucose and the cg19693031 methylation site. While adjusting for the genetic signal rs183499598, a stronger association ($\beta_{\text{eff}} = 0.003$, $P = 5.94 \times 10^{-3}$) between WC and the cg11024682 methylation site was observed (Table 4).
Discussion

We performed EWAS of MetS and its components to shed light on the biological background of this complex phenotype. In an interpretation of the results the evident overlapping interrelation of separate component traits of MetS should be taken into account. In should also be noted that medication is in general a known epigenome altering factor. Nevertheless we believe that our analyses capture rather association signals induced by studied phenotypes than by individual drug ingredients used by study individuals (Supplementary material, Supplementary Table 3). Our data suggest that the interplay between lipid and glucose metabolism may represent a key element in the pathology of MetS, implying that epigenetic markers linking blood pressure to the other components of MetS may be scarce.

The role of replicated methylation loci in metabolism. We observed numerous associations between CpG methylation sites and separate component phenotypes of MetS. The essential role of dyslipidemia in MetS was previously suggested. Our data support the view that the biological background of MetS strongly points...
towards alterations in lipid metabolism. Methylation site cg06500161 in gene ABCG1 associated with triglycerides and WC in our primary EW AS and suggested an association with HDL, glucose, and MetS as a condition. We also saw a clear inverse correlation between the methylation locus and the gene expression of ABCG1 indicating the possible changes in gene function related to the methylation of cg06500161. The association between cg06500161 and triglyceride and HDL metabolism was previously reported, and the locus appears to act as an epigenetic link between myocardial infarction and the blood lipid levels. In addition, the methylation site was previously found to act as an integral part of insulin and glucose metabolism, as well as associating with homeostatic model assessment for insulin resistance (HOMA-IR), a commonly used surrogate to define the state of insulin resistance. Cg06500161 is also directly associated with type 2 diabetes, and appears to serve as an epigenetic marker when evaluating an individual’s risk for it. Recent study directly linked the site to MetS. Our data support the idea that the ABCG1 gene plays an important role in both lipid and glucose metabolism, suggesting that it could potentially link the two as an underlying factor in the pathology of MetS. In a recent study, support for the hypothesized role of body mass index as a factor partly explaining the association between type 2 diabetes and DNA methylation was given. Our data suggests that these findings can be seen in a broader context of MetS-related dyslipidaemia as a preceding state of type 2 diabetes.

Table 4. Conditional analysis for the replicated CpG M value—phenotype associations. DILGOM dietary, lifestyle, and genetic determinants of obesity and metabolic syndrome, WC waist circumference, CpG cytosine–guanine dinucleotide, SNP single-nucleotide polymorphism, SE standard error.

| Phenotype | CpG     | Position (Chr.bp) | Gene | Strand | Relation to UCSC CpG Island | Enhancer       | Regulatory Feature Group | DMR Transcript | n | Effect | SE  | P            |
|-----------|---------|-------------------|------|--------|----------------------------|----------------|--------------------------|----------------|----|--------|-----|-------------|
| Fasting glucose | cg19693031 | 1:145,441,552 | TXNIP | F       | 3′UTR | -                         | -              | -                        | ILMN 1697448   | 512 | -0.004  | 0.07  | 0.95        |
| HDL       | cg17901584 | 1:55,353,706   | DHCR24 | F       | TSS1500 | S_Shore | -                        | -              | NA | NA     | NA  | NA          |
| Triglycerides | cg06500161 | 21:43,656,587 | ABCG1 | F       | Body | S_Shore | TRUE | -                        | ILMN 1695378   | 512 | 0.087  | 0.14  | 0.0043      |
| WC        | cg11024682 | 17:17,730,094  | SREBF1 | R       | Body | S_Shelf | -                       | -              | NA | NA     | NA  | NA          |
|           | cg08309687 | 21:35,320,596  |       | F       | TRUE | Promoter Associated | DMR  | NA                       | NA  | NA     | NA  | NA          |

Table 5. Gene expression—CpG M value associations of successfully replicated CpG methylation sites. CpG cytosine–guanine dinucleotide, Chr chromosome, bp base pair, GRCh37 the Genome Reference Consortium human genome (build 37), UCSC University of California Santa Cruz, DMR differentially methylated region, SE standard error. Annotation information for CpG methylation sites is received from the annotation file of Illumina Infinium Human Methylation 450 BeadChip.

| CpG     | Position (Chr.bp) | Gene | Strand | Relation to UCSC CpG Island | Enhancer       | Regulatory Feature Group | DMR Transcript | n | Effect | SE  | P            |
|---------|-------------------|------|--------|----------------------------|----------------|--------------------------|----------------|----|--------|-----|-------------|
| cg19693031 | 1:145,441,552 | TXNIP | F       | 3′UTR | -                         | -              | -                        | ILMN 1697448   | 512 | -0.004  | 0.07  | 0.95        |
| cg17901584 | 1:55,353,706 | DHCR24 | F       | TSS1500 | S_Shore | -                        | -              | ILMN 1663035   | 512 | -0.119  | 0.06  | 0.045       |
| cg11024682 | 17:17,730,094 | SREBF1 | R       | Body | S_Shelf | -                       | ILMN 1695378   | 512 | 0.087  | 0.06  | 0.14        |
| cg06500161 | 21:43,656,587 | ABCG1 | F       | Body | S_Shore | TRUE | -                        | ILMN 1695968 | 512 | 0.038  | 0.04  | 0.32        |
| cg08309687 | 21:35,320,596 |       | F       | TRUE | Promoter Associated | DMR | NA                        | NA  | NA     | NA  | NA          |
Cg11024682 in the SREBF1 gene associated with WC in our primary analysis suggesting an association with triglycerides and MetS. The association between cg11024682 and triglycerides has been previously identified, whereby the results were validated through a tissue-specific analysis using adipose and skin tissue. In addition, an interaction between the gene products of ABCG1 and SREBF1 has also been reported. Furthermore, evidence suggests that the role of SREBF1 in glucose metabolism and type 2 diabetes. While we found no association between glucose metabolism and SREBF1 in our analyses, our findings link the function of SREBF1 to MetS, thus supporting the concept of an altered lipid metabolism related to the syndrome. The possible effect of cg11024682 methylation locus on expression of SREBF1 was supported by our findings. Our suggestive finding about the possible interaction between the methylation locus at SREBF1 and the expression of ABCG1 further support the idea about the interaction between the two genes.

The third replicated methylation site associated with WC in our data, cg08309687 located in the intergenic area downstream from the ABCG1 gene region, suggested a correlation with triglyceride levels. Interestingly, in a family study attempting to identify novel epigenetic determinants of type 2 diabetes, this methylation site represented one of the most significant CpG sites directly associated with type 2 diabetes, along with fasting glucose and insulin resistance. To our knowledge, our study is the first to also link this methylation site to lipids metabolism.

Additionally, we report the novel association between cg17901584 in chromosome 1 and HDL as well as the association between this methylation site and triglycerides and WC. This is, to our knowledge, the first time that cg17901584, located approximately 1 kb downstream from 24-dehydrocholesterol reductase (DHCR24) has been linked to lipid metabolism at the methylation level.

The methylation site cg19693031 in the gene TXNIP was previously found to associate with lipid metabolism, and its role in glucose metabolism and type 2 diabetes has been confirmed in many recent studies. Our data also indicates that cg19693031 is indeed an important methylation site, possibly linking lipid and glucose metabolism to each other. In our association analyses between cg19693031 methylation locus and gene expression we could see that rather than affecting the expression of its "own" gene TXNIP the locus shows association with the expression of lipid associated genes SREBF1 and ABCG1. Notably, in our analyses, cg19693031 was the only successfully replicated methylation site binding all of the different components together with MetS. In our search for methylation loci linking the individual MetS components together as a pathological cardiometabolic condition, cg19693031 in the TXNIP gene appears to represent a strong candidate.

Blood pressure as a component of MetS. Our data identified the rather independent behaviour of blood pressure components on MetS compared to the metabolic components of the syndrome, as well as the non-aligned behaviour between diastolic and systolic blood pressure (Fig. 1). Only one of the four probes showing suggestive association with blood pressure on top of the other components of MetS, cg19693031, was replicated. Thus, any successfully replicated connective epigenetic marker can serve as a solid target in future studies of the MetS biology. We should also note that the mean age of the replication cohort of our study is rather low, possibly explaining the small replication rate among the blood pressure-related probes in our analyses (Table 1). At the genetic level, the association between the TXNIP allele variation, type 2 diabetes, and hypertension was previously demonstrated in a study linking the diabetogenic and vascular pathways behind metabolic conditions has been discussed. To our knowledge, however, our study is the first to suggest that the methylation component should also be considered in such discussions.

In our study, the non-replicated methylation probe cg07699454 appeared to associate with MetS and its lipid components, as well as with diastolic blood pressure. This probe is located in the gene KCNK17, which has previously been associated with a risk of stroke. It also resides in close proximity to the gene KCNK16, a known susceptibility locus for type 2 diabetes. These findings render cg07699454 an interesting locus for future studies on the role of vascular components of type 2 diabetes and MetS. The apparent association between cg06500161 and diastolic blood pressure in the NFBC1966 represents an interesting finding. The well-characterised ABCG1 gene has only very recently been associated with vascular phenotypes. Our data also support the previous idea that cg06500161 could represent a target locus in further studies regarding the molecular background of MetS.

Strengths and limitations. Our study has several strengths. Finnish population cohorts are, in general, homogeneous, both genetically and culturally well characterised, making biological patterns detectable even amongst relatively small sample sizes. In addition, a detailed cohort characterisation also helped to construct analytical models in a harmonious way, which is crucial when attempting to control the challenging nature of methylation data. We observe a slightly increased pattern of general hypomethylation in association analyses performed in the discovery cohort with older individuals, compared to the younger replication cohort. The finding, even though should be examined with a caution, fits well with the general observation about promoting effect of aging leading to a global genome-wide hypomethylation in various types of tissues. We should, however, address some limitations. As discussed in a wide range of EWASes, whole-blood peripheral white blood cells are not ideal sources of methylation data, since methylation as a form of regulation mechanism is highly tissue-specific. Furthermore, due to methylation's great sensitivity to variation in age, our replication cohort may not be the best possible cohort for the purpose and may in part explain the relatively modest success in replication.
of our findings. However, because of the notable age-difference between discovery and replication cohorts, the statistical power of detecting true positive findings diminishes. Thus we feel that the risk of detecting and reporting false positive findings in our study remains small. We also recognise the role of elevated waist circumference as a prerequisite of MetS condition in 2005 IDF definition for MetS, and it cannot be ruled out that associations that we see between different methylation sites and MetS might for one manifest the association between methylation site and waist circumference.

Conclusions
Taken together, our study links the previously type 2 diabetes–associated methylation locus cg08309687 to lipid metabolism. We also found a novel association between the methylation locus cg17901584 and HDL. Overall, our study supports the idea derived from genetic studies whereby aberrations in lipid metabolism, combined with the interplay with glucose metabolism, play central roles as functional elements of MetS. In our study we consider EWAS as a tool of a hypothesis free approach to examine if epigenetic variation explains any variation in the phenotype to be studied. The epigenetics of MetS appear polymorphic as expected. Our data suggest that blood pressure might act rather independently compared to the metabolic components of MetS, at least at the epigenetic level. In our attempt to identify a comprehensive methylation locus behind the MetS condition, cg19693031 in gene TXNIP emerges as a strong candidate.

Data availability
The data that support the findings of this study are available from THL Biobank and University of Oulu but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of THL Biobank and University of Oulu.

Received: 26 March 2019; Accepted: 9 November 2020
Published online: 25 November 2020

References
1. Alberti, K. G., Zimet, P., Shaw, J. & IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet 366, 1059–1062 (2005).
2. Ford, E. S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28, 1769–1778 (2005).
3. Zabaneh, D. & Balding, D. J. A genome-wide association study of the metabolic syndrome in Indian Asian men. PLoS ONE 5, e11961 (2010).
4. Kraja, A. T. et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes 60, 1329–1339 (2011).
5. Avery, C. L. et al. A phenomns-based strategy identifies loci on APOC1, BRF, and PCLG1 associated with metabolic syndrome phenotype domains. PLoS Genet. 7, e1002522 (2011).
6. Kristiansson, K. et al. Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ. Cardiovasc. Genet. 5, 242–249 (2012).
7. Stanicakova, A. & Laakso, M. Genetics of metabolic syndrome. Rev. Endocr. Metab. Disord. 15, 243–252 (2014).
8. Das, M. et al. Association of DNA Methylation at CPT1A Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study. PLoS ONE 11, e0145799 (2016).
9. Zhang, Y. et al. Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a Northern European family population. BMC Med. Genom. 6, 9 (2013).
10. Akinremi, T. et al. Epigenome-wide association study of metabolic syndrome in African-American adults. ClinEpigenet. 10, 49 (2018).
11. Borodulin, K. et al. Cohort profile: the national FINRISK study. Int. J. Epidemiol. 47, 696–696 (2018).
12. Inouye, M. et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol. Syst. Biol. 6, 441 (2010).
13. van Vliet-Ostaptchouk, J. V. et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr. Disord. 14, 9 (2014).
14. Herder, C. et al. Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits. Diabetes 63, 4343–4359 (2014).
15. Rantakallio, P. Groups at risk in low birth weight infants and perinatal mortality. Acta Paediatr Scand. 193, 1–71 (1969).
16. Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363–1369 (2014).
17. Makimovski, J., Gordon, J. & Oshlack, A. SW AN: Subset-quantile within array normalization for Illumina Infinium HumanMethylation450 BeadChips. Genome Biol. 13, R44 (2012).
18. Lehne, B. et al. A coherent approach for analysis of the Illumina HumanMethylation450 BeadChip improves data quality and performance in epigenome-wide association studies. Genome Biol. 16, 17 (2015).
19. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-seqencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
20. Housman, E. A. et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinf. 13, 86 (2012).
21. Graw, S. et al. pwrEWAS: a user-friendly tool for comprehensive power estimation for epigenome wide association studies (EWAS). BMC Bioinf. 20, 218 (2019).
22. R Core Team. R: A language and environment for statistical computing. Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/ (2016).
23. Magi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. BMC Bioinf. 11, 288 (2010).
24. Inouye, M. et al. An immune response network associated with blood lipid levels. PLoS Genet. 6, e1001133 (2010).
25. Pfeiffer, L. et al. DNA methylation of lipid-related genes affects blood lipid levels. Circ. Cardiovasc. Genet. 8, 334–342 (2015).
26. Kriebel, J. et al. Association between DNA methylation in whole blood and measures of glucose metabolism: KORA F4 study. PLoS ONE 11, e0152314 (2016).
27. Hidalgo, B. et al. Epigenome-wide association study of fasting measures of glucose, insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network study. Diabetes 63, 801–807 (2014).
28. Kulkarni, H. et al. Novel epigenetic determinants of type 2 diabetes in Mexican-American families. Hum. Mol. Genet. 24, 5330–5344 (2015).
29. Walaszczyk, E. et al. DNA methylation markers associated with type 2 diabetes, fasting glucose and HbA1c levels: a systematic review and replication in a case-control sample of the Lifelines study. Diabetologia 61, 354–368 (2018).
30. Chambers, J. C. et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study. Lancet Diabetes Endocrinol. 3, 526–534 (2015).
31. Petersen, A. K. et al. Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits. Hum. Mol. Genet. 23, 534–545 (2014).
32. Florath, I. et al. Type 2 diabetes and leukocyte DNA methylation: an epigenome-wide association study in over 1,500 older adults. Diabetologia 59, 130–138 (2016).
33. Soriano-Tarraga, C. et al. Epigenome-wide association study identifies TXNIP gene associated with type 2 diabetes mellitus and sustained hyperglycaemia. Hum. Mol. Genet. 25, 609–619 (2016).
34. van Greevenbroek, M. M. et al. Genetic variation in thioredoxin interacting protein (TXNIP) is associated with hypertriglyceridemia and blood pressure in diabetes mellitus. Diabet. Med. 24, 498–504 (2007).
35. Ferreira, N. E. et al. Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. Atherosclerosis 221, 131–136 (2012).
36. Matarin, M. et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol. 6, 414–420 (2007).
37. Cho, Y. S. et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat. Genet. 44, 67–72 (2011).
38. Huang, Y. et al. Identification, heritability, and relation with gene expression of novel DNA methylation loci for blood pressure. Hypertension 76, 195–205 (2020).

Acknowledgements
We wish to thank the participants from the cohorts for their voluntary participation in these studies. The skilful work of the National Institute for Health and Welfare (THL) DNA laboratory is acknowledged for its handling of the samples. DILGOM methylation and GWAS data were financially supported by Academy of Finland grants no. 255935 and 269517. This project was also financially supported by European Union’s Policy Framework (FP7) under grant agreements no. 313010 (BBMRI-LPC), no. 305280 (MIMOmics), and HZ2020 633589 (Ageing with Elegans), as well as by the Yrjö Jahnsson Foundation and the Finnish Foundation for Cardiovascular Research. The Estonian Genome Centre acknowledges support through EU Horizon 2020 grants 692145, 676550, and 654248, Estonian Research Council Grant IUT20-60, and PerMed I, NIASC, EIT – Health and European Union through the European Regional development Fund (Project No, 2014-2020.4.01.15-0012 GENTRANSMED). NFBC1966 received financial support from University of Oulu Grant no. 65354, Oulu University Hospital Grant no. 2/97, 8/97, Ministry of Health and Social Affairs Grant no. 23/251/97, 160/97, 190/97, National Institute for Health and Welfare, Helsinki Grant no. 54121, Regional Institute of Occupational Health, Oulu, Finland Grant no. 50621, 54231. NFBC1966 wishes to thank the late professor Paula Kantakallio (launch of NFBC1966), the participants in the 31yrs study and the NFBC project center. M.L.N. received support through grants from the Emil Aaltonen Foundation, the Finnish Foundation for Cardiovascular Research, Ida Montin Foundation and the Finnish Medical Society Duodecim. V.S. received support from the Finnish Foundation for Cardiovascular Research. K.K. received support from the Academy of Finland (grant no. 250207). A.I. received support from the Finnish Foundation for Cardiovascular Research and Biomedicum Helsinki Foundation. J.K. was supported through funds from the Academy of Finland (grant numbers 297338 and 307247) and Novo Nordisk Fonden (grant number NNF17OC0026062). M.L.N., K.K., and M.P. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Preliminary results of the project were presented by M.L.N. in a poster session of the American Society of Human Genetics meeting held in Vancouver, Canada in 2016.

Author contributions
M.L.N., N.P., K.K. and M.P. conceived and designed the study. M.L.N., N.P., A.J., V.K., T.H., L.M., J.K., M.R.J., P.J., A.M., V.S., K.K. and M.P. contributed to and researched the data. M.L.N., N.P., A.J., V.K., T.H., J.K., V.S., K.K. and M.P. analysed the data and contributed to the discussion. M.L.N., N.P., A.J., V.K. and K.K. wrote the manuscript. All co-authors reviewed and edited the manuscript, and approved the final version prior to submission.

Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
J.K. reports owning stock options for Nightingale Health. V.S. has received honoraria from Novo Nordisk and Sanofi for consulting. He also has ongoing research collaboration with Bayer Ltd. (All unrelated to the present study). K.K. is a shareholder in companies DIAMYD MEDICAL AB, NEGEN OY, and TERVEYSTALO OYJ (less than 5% of shares). She worked part-time in NEGEN OY until January 2018. A.J. works part-time in NEGEN OY.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-77506-z.
Correspondence and requests for materials should be addressed to M.-L.N.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020